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Abstract
Triple Negative Breast Cancer (TNBC), the most aggressive subtype of breast cancer, is
characterized by the absence of hormone receptors usually targeted by hormone therapies
like Tamoxifen. Because therapy success and survival rates for TNBC lag far behind other
breast cancer subtypes, there is significant interest in developing novel anti-TNBC agents
that can target TNBC specifically, with minimal effects on non-malignant tissue. To this aim,
our study describes the anti-TNBC effect of strictinin, an ellagitanin previously isolated from
Myrothamnus flabellifolius. Using various in silico and molecular techniques, we character-
ized the mechanism of action of strictinin in TNBC. Our results suggest strictinin interacts
strongly with Receptor Tyrosine Kinase Orphan like 1 (ROR1). ROR1 is an oncofetal recep-
tor highly expressed during development but not in normal adult tissue. It is highly expressed
in several human malignancies however, owing to its numerous pro-tumor functions. Via its
interaction and inhibition of ROR1, strictinin reduced AKT phosphorylation on ser-473, inhib-
iting downstream phosphorylation and inhibition of GSK3β. The reduction in AKT phosphor-
ylation also correlated with decreased cell survival and activation of the caspase-mediated
intrinsic apoptotic cascade. Strictinin treatment also repressed cell migration and invasion in
a beta-catenin independent manner, presumably via the reactivated GSK3ß’s repressing
effect on microtubule polymerization and focal adhesion turnover. This could be of potential
therapeutic interest considering heightened interest in ROR1 and other receptor tyrosine
kinases as targets for development of anti-cancer agents. Further studies are needed to val-
idate these findings in other ROR1-expressing malignancies but also in more systemic mod-
els of TNBC. Our findings do however underline the potential of strictinin and other ROR1-
targeting agents as therapeutic tools to reduce TNBC proliferation, survival and motility.
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Introduction
Approximately one in eight women are diagnosed with breast cancer each year. Of these new
cases, 15–20% are Triple Negative [1]. Triple Negative Breast Cancer (TNBC) is an aggressive
subtype of breast cancer characterized by malignant cells void of hormone (Progesterone and
Estrogen) receptors and Human Epidermal Growth Factor Receptor 2 (HER-2) [2]. The lack
of these receptors, usually targeted by hormonal therapies like tamoxifen and fulvestrant, leads
to an increased difficulty in treatment. Owing to its increased propensity for metastasis and
invasion, TNBC prognosis and long-term survival is significantly worse than in other breast
cancer subtypes [3]. In addition, traditional chemotherapeutics and radiation used in breast
cancer therapy are often highly toxic to both TNBC cells and healthy cells. This leads to many
negative and unwanted side effects, often causing a decrease in therapy adherence in patients.
In recent years, there has thus been an increased effort to look for novel agents that can treat
triple negative breast cancer or complement existing drugs, with minimal effects on non-
malignant cells.
Phyto-compounds with anti-cancer activity that can selectively target TNBC with minimal
effects on non-malignant cells have emerged as viable therapeutic agents for TNBC. We previ-
ously isolated strictinin (Chemical name: 3-O-galloyl-4,6-[(S)- hexahydroxydiphenoyl]-b-d-
glucopyranose), from Myrothamnus flabellifolius, a South African medicinal plant with anti-
cancer properties [4,5]. Strictinin was shown to have pronounced anti-TNBC activity with
minimal activity on the non-malignant MCF-10A breast epithelial line.
To identify the molecular targets of strictinin in TNBC, we used its structure to search
drugs in DrugBank [6] with 0.75 of structure similarity threshold, one hit with 0.795 of similar-
ity score was obtained: an experimental drug named 1,2,3,4,6-Pentagalloyl glucose (DB03208).
Although the targets of DB03208 were not reported in DrugBank, a recent in-silico drug dis-
covery study [7] suggest DB03208 is a potential cancer drug by inhibiting the activity of Recep-
tor Orphan Tyrosine Kinase-like Receptor-1 (ROR1), an oncofetal receptor present during
embryonic development but absent or expressed minimally in normal adult tissue. It is how-
ever highly expressed in several human malignancies including breast, ovarian, lung, lym-
phoma, skin, pancreatic, testicular, uterus, prostate and adrenal cancers [8,9]. Therefore, we
hypothesized that strictinin acts as an ROR1 inhibitor just like DB03208.
The ROR1 protein is a member of the RTK-family of tyrosine kinase receptors but interest-
ingly lacks any significant kinase activity [10]. Structurally, it contains an extracellular Ig-like
domain, a cysteine-rich domain, a Frizzled domain, a kringle domain, a transmembrane domain
with tyrosine kinase, serine/threonine-rich and proline-rich domains on the cytoplasmic side
[11]. Functionally, upon binding of its ligand (Wnt3/5a), it interacts with the non-canonical Wnt
signaling pathway, activating Wnt-responsive genes in a beta-catenin independent manner
[12,13]. This culminates in EMT-induction and proliferation [14]. It also promotes AKT phos-
phorylation at serine-473 potentially through its interaction with casein kinase1ε (CK1ε) [8]
resulting in increased cell survival, proliferation and migration. It has emerged in recent years as a
target of significant interest for immunotherapy and drug discovery [15–17].
Here we report that strictinin inhibits ROR1 activity, reducing downstream phosphoryla-
tion and activation of AKT by P13K on serine-473. This coincided with reduced TNBC sur-
vival and induction of intrinsic apoptosis via inhibition of Bad phosphorylation and cleavage
of caspase 9. We also observed a reduction in GSK3ß phosphorylation at serine-9 by p-AKT, a
process which inhibits its activity. The newly “re-activated” GSK3ß, presumably via its action
on microtubule dynamics and maturation of nascent focal adhesions repressed TNBC cell
motility in a beta-catenin independent manner. Our results describe the anti-proliferative and
anti-metastatic potential of strictinin as an anti-TNBC agent and underlines the intersection of
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TNBC lines MDA-MB231 (ATCC HTB 26), BT549 (ATCC HTB122) and Normal Human
Breast Epithelial cell line (MCF-10A) (ATCC CRL-10317) are cultured as per ATCC recom-
mendations. MDA-MB-231cells were cultured in DMEM/F-12 (Lonza, Basel, Switzerland)
supplemented with FBS (10%), insulin (10μg/ml), non-essential amino acids, sodium pyruvate,
penicillin (100 U/ml) and streptomycin (0.1 mg/ml). BT-549 cells were cultured in RPMI
(Lonza, Basel, Switzerland), with FBS (10%), insulin (10μg/ml), and penicillin (100 U/ml) and
streptomycin (0.1 mg/ml). MCF-10A was grown in DMEM/F-12 with 5% horse serum
(ATCC, Manassas, VA, USA), insulin (10μg/ml), hydrocortisone (0.5 mg/ml), EGF (20ng/ml),
penicillin (100 U/ml) and streptomycin (0.1 mg/ml). All cells were kept at 37˚C with 5% CO2.
MTT assay
MTT assays (Thermofisher, Waltham, MA, USA) were used to assess proliferation and viabil-
ity. Cells were seeded in a 96-well plate at a density of 25,000 cells/well. Strictinin, dissolved in
DMSO (final DMSO concentration< 0.3%) was added to the cells. A 0.3% DMSO vehicle con-
trol group was also included in all analyses. After 24-72h, treatment media was replaced with
fresh media and MTT dye added. Following a 2-hr incubation at 37˚C, DMSO was added and
absorbance read at 540 nm. Cell viability was calculated as percentage of no-treatment control.
In silico docking analysis
Ligand and protein structure. 3D structures of the ligands, DB03208 and strictinin, were
built in Schrodinger’s Maestro. For each ligand, the tautomeric states were generated at pH = 7
using Maestro’s Epik [18,19]. The lowest tautomeric state was selected and then minimized to
the most energetically favorable structure. Receptor Tyrosine Kinase-like Orphan Receptor 1
(ROR1) has an extracellular domain, a transmembrane domain, and an intracellular domain.
We modeled a truncated version of ROR1 (tROR1) that is identical with the intracellular, C-
terminal region of ROR1 but does not contain the transmembrane nor the extracellular
domains. The sequence for tROR1 (AAC50714.1) was retrieved from the NCBI protein data-
base. The 3D structure of tROR1 (Fig 1) was then predicted using I-TASSER [20–22]. The
model for tROR1 was then preprocessed, optimized, and minimized using Maestro’s Protein
Preparation Wizard [23]. We then mapped for active sites using Maestro’s SiteMap [24,25].
Ligand docking. The active site (S1A Fig) we chose was the one closest to the residues
indicated in a previous docking of DB03208 to tROR1 by Nath et Al [7]. A receptor grid was
generated around the active site of tROR1. DB03208 and Strictinin were individually docked
to tROR1 using Glide docking followed by Induced Fit Docking [26–31]. To check the validity
of our docking, we compared our ligand interaction diagram to that of Nath et Al [7]. Our
DB03208 ligand interactions showed many similar residue interactions to theirs (S1B and S1C
Fig). The binding site of strictinin is very close to the binding site of DB03208 (S1D Fig), sug-
gesting these two ligands might have similar drug action against tROR1.
Immunoblotting
Following various treatments, the cells were washed once in 1X PBS and lysed with RIPA
buffer (150 mM NaCl, 1.0% Triton-X-100, 0.5% Sodium deoxycholate, 0.1% SDS, 50 mM Tris,
Strictinin inhibits ROR1 and represses TNBC survival and migration
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pH 8.0) with 1 mM PMSF. Protein concentrations were determined by Bradford Assay using
Pierce 660 nm Protein Assay reagent (thermofisher, Waltham, MA, USA). Following
SDS-PAGE, Proteins were transferred to nitrocellulose membranes, which were blocked for
Fig 1. Strictinin interacts with ROR1 in TNBC. a) Homology Model of tROR1. Whereas N-terminus is indicated by a red ball, C-terminus is indicated
by a blue ball. b, c) Strictinin docked to tROR1 and ligand interactions diagram. Whereas N-terminus is indicated by a red ball, C-terminus is indicated
by a blue ball. d, e) Immunoblot and immunofluorescence investigating basal ROR1 expression in two TNBC lines and non-malignant breast epithelial
line, MCF-10A. f) MTT assessing effect of ROR1 siRNA knockdown on strictinin cytotoxicity in TNBC. g) Immunoblot showing effect of siROR1
knockdown and strictinin on ROR1 expression in MDA-MB-231. h) Co-immunoprecipitation of ROR1 receptor showing inhibition of Wnt-5a binding
to ROR1 after strictinin treatment. (� = p.value<0.05, n = 3).
https://doi.org/10.1371/journal.pone.0217789.g001
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1-hour in 5% milk with gentle agitation. Membranes were incubated overnight at 4˚C with
various antibodies then washed in TBS-T (20mM Tris, 150mM NaCl, 0.1% Tween 20), and
incubated for 1-hour at room temperature with horseradish-peroxidase-linked anti-Mouse or
anti-Rabbit IgGs (Cell Signaling, Danvers, MA, USA). Protein bands were detected by chemi-
luminescence. Antibodies: ROR1 (Cell signal, #D6T8C), GAPDH (Cell signal, #D16H11),
CK1ε (Cell signal, #12448S), p-AKT-ser473 (Cell signal, #9271S), AKT (Cell signal, #C67E7),
p-GSK3β-ser9 (Cell signal, #D17D2), GSK3β (Cell signal, #D7SD3), XIAP (Cell signal,
#D2Z8UL), caspase-9 (Cell signal, #9502S), Bad (Cell signal, #D24A9), p-Bad-ser136 (Cell sig-
nal, #4366T), β-catenin (Invitrogen, MA1-301), p-β-catenin-ser33/37, Wint-5a (Novus-Bio
NBP2-24752SS)
Co-immunoprecipitation
Co-immunoprecipitation of ROR1 and its interacting proteins was performed using the Pierce
Classic IP Kit (thermofisher, # 26146) according to manufacturer protocol. Briefly, following
treatments, cells were lysed in a moderate-strength IP-Lysis buffer without SDS (thermofisher,
#87787) and protein quantified by Bradford assay. For each condition, 1μg of protein was
incubated with Rabbit IgG anti-ROR1 ab (Cell signal, #D6T8C) at 1:100 (final volume 300 μl
in IP-lysis buffer) on a nutator overnight at 4˚C. The ROR1 immune complex was captured by
centrifugation in a Protein A/G agarose-resin column and eluted by centrifugation using non-
reducing sample buffer with DTT. Following boiling, the eluted samples were analyzed by
western blot as previously described.
Immunofluorescence
Cells were plated at a density of 3000 cells/well in wells of Lab-Tek chamber slides (Sigma-
Aldrich, St. Louis, MO, USA) and fixed with pre-chilled methanol for 5 minutes at -20˚C. Fol-
lowing three PBS rinses, cells were incubated overnight in primary antibody diluted in 5%
BSA/PBS. Cells were once again rinsed with PBS and incubated at 37˚C with Alexa-fluor-555
(Thermofisher, Waltham, MA, USA) secondary antibody in 5% BSA/PBS for an hour. Follow-
ing three PBS washes, cells were incubated in DAPI stain solution (0.2μg/ml in PBS) for 2 min-
utes at room temperature. After an additional 3 PBS washes, the cells were imaged via confocal
microscopy on a Leica DMi8 Microscope (Leica, Wetzlar, Germany).
Foxo luciferase assay
P13K/AKT activity was assessed using a FOXO luciferase reporter (BPS bioscience, #60643,
San Diego, CA, USA) according to manufacturer’s protocol. Briefly, TNBC cells were trans-
fected with a construct encoding a firefly luciferase gene under the control of FOXO respon-
sive elements which are targets of the P13K/AKT pathway. Following treatments, cells were
lysed and luciferase activity assessed using Promega’s Dual-Luciferase Reporter Assay System
(Promega, E1910, Madison, WI, USA).
RNAi knockdown of ROR1
ROR1-siRNA (Thermofisher, AM16708) was transfected into cells using Lipofectamine RNAi/
Max reagent (Thermofisher, Waltham, MA, USA) according to manufacturer protocol.
Briefly, cells were transfected with siROR1 for 24h in Opti-MEM (Thermofisher, Waltham,
MA, USA) then rescued in full culture media for 2 hours before treatment or lysing for
protein.
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Annexin-V/FITC staining: Annexin-V/FITC staining to assess apoptosis after Strictinin
treatment was performed using the Muse Annexin V and Dead Cell Assay Kit (Emdmillipore,
MCH100105, Burlington, MA, USA) according to the manufacturer’s protocol. Briefly, treated
cells were trypsinized and re-suspended in fresh culture media before addition of Annexin-V/
FITC dye solution. Stained cells were analyzed for apoptosis by FACS using a Muse Cell Analyzer.
Wound healing assay
Wound healing assays to assess cell migration were conducted in 24-well plates. 150,000 cells
were seeded in each well and allowed to propagate for 24h to get a confluent monolayer. Cells
were then treated with appropriate treatments for 24h. A 10μl pipette tip was used to make a
wound on the monolayer and an inverted phase contrast microscope was used to visualize and
take pictures of the wound. Quantification of wound size was done on ImageJ and percent
migrated calculated as percentage of wound closed.
Invasion assay
Boyden chamber assays to assess cell invasion were conducted in 24-well plates with a Cultrex
24 Insert Cell Invasion / Migration Chamber (Trevigen, 3455-024-01, Gaithersburg, MD,
USA). Cells were serum starved for 24h before being seeded in the top chamber of the trans-
well set-up. Following treatment, complete culture media containing FBS was added to the
bottom chamber. At varying time points, both complete culture media and cell solution were
aspirated off and the membrane washed with PBS before crystal violet staining and phase con-
trast imaging. Quantification of migrated cells was done using ImageJ.
Isothermal titration calorimetry
Binding affinity of Strictinin to ROR1 was conducted using an Affinity ITC (TA Instruments).
Recombinant ROR1 (Peprotech, 160–04) was prepared in (0.1% DMSO in molecular grade
water)to a final concentration of 13.8 μM and placed in the ITC cell. Strictinin was prepared in
the identical buffer to a final concentration of 276 μM and placed in the syringe. Samples were
loaded manually and data were collected at 37˚C. Data were analyzed using NanoAnalyze
v3.8.0 (TA Instruments) and Origin 2016 (OriginLab) was used to prepare the figure.
Results
Strictinin interacts with ROR1 in TNBC
To support our hypothesis that strictinin can interact with ROR1 in a similar way as DB03008,
we did in silico docking analyses of DB03208 and strictinin with ROR1. Induced fit docking
for DB03208 and strictinin to the similar site resulted in a tight binding for both ligands (Fig
1B and 1C). DB03208 had a Glide gscore of -11.4 kcal/mol while strictinin had a Glide gscore
of -7.7 kcal/mol (Table 1). MM-GBSA calculations were also run resulting in -116.8 kcal/mol
for DB03208 and -97.8 kcal/mol for strictinin. Given the moderate binding affinity at the simi-
lar binding site of DB03208, it is plausible that strictinin interact with ROR1 just like DB03208.
The detailed ligand-protein interaction for strictinin is shown in Fig 1.
Table 1. Glide scores of DB03208 and Rx7.
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To experimentally evaluate whether strictinin binds ROR1, we next employed isothermal
titration calorimetry. Indeed, the binding isotherm indicates a direct binding interaction with
low micromolar affinity (S1E Fig). Strictinin binding is enthalpically driven and confirms a
one-to-one binding stoichiometry with ROR1. To validate our in silico and ITC findings, we
set out to knockdown ROR1 expression in TNBC cell lines and observe the effect on strictinin
cytotoxicity. First we assessed basal ROR1 expression in our two TNBC cell lines (MDA-MB-
231 and BT-549) and one non-malignant cell line (MCF-10A). We found high expression of
ROR1 in both TNBC cell lines with minimal expression in the non-malignant cell line MCF-
10A (Fig 1D and 1E). We then conducted cell viability assays after siRNA knockdown of
ROR1 in both TNBC cell lines and observed repression of strictinin cytotoxicity (Fig 1F and
1G). Further corroborating our results that strictinin interacts with ROR1, we also observed
inhibition of Wnt-5a binding to ROR1 after treatment with strictinin (Fig 1H). Altogether, the
ITC, co-immunoprecipitation, and the siROR1 cell viability data provide evidence that stricti-
nin binds competitively to ROR1.
Strictinin inhibits AKT phosphorylation and GSK3ß inhibition
The ROR1 signaling pathway culminates in activation of AKT via phosphorylation on serine-
473 by P13K (Fig 2A). To investigate disruption of this phosphorylation event and the P13K/
AKT pathway at large, we used a FOXO-luciferase reporter assay which directly measures
Fig 2. Strictinin inhibits AKT phosphorylation and downstream GSK3ß phosphorylation. a) The ROR1 signaling network as
currently understood. b) FOXO-luciferase assay assessing srtictinin effect on P13K/AKT activity in MDA-MB-231 after 24h. c)
Immunoblots assessing strictinin effect on AKT phosphorylation at serine 473 and GSK3β phosphorylation at serine 9. (� =
p.value<0.05, n = 3).
https://doi.org/10.1371/journal.pone.0217789.g002
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activity of the P13K/AKT pathway. We observed a decrease in P13K/AKT activity in the TNBC
cell lines after treatment with 62.5 and 125 μg/ml of strictinin for 24h (Fig 2B, S2A Fig). Further
corroborating our results were immunoblots which showed a time-dependent decrease in p-
AKT (ser9) levels after TNBC cell treatment with strictinin, an effect which was reversed in the
MCF-10A line (Fig 2C). Because recruitment of CK1ε by ROR1 had been previously shown to
be necessary for its stimulatory activity on P13K/AKT, we used co-immunoprecipitation to
assess CK1ε binding to ROR1 after strictinin treatment. However, we observed no significant
change in ROR1-bound CK1ε levels after strictinin treatment (S2B Fig).
Strictinin induces apoptosis and reduces cell survival
Because ROR1 activity and activation of AKT has been shown to promote cancer cell survival
and inhibit apoptosis [8], we used Annexin-V/FITC staining to assess apoptosis induction
after strictinin treatment. Flow cytometric analyses of the stained cells revealed strictinin treat-
ment induced a dose-dependent increase in apoptosis in the two TNBC cell lines but not in
the MCF-10A cell line (Fig 3A and 3B). Immunoblots also revealed a decrease in XIAP levels
and Bad phosphorylation on serine-136 after treatment with strictinin. This culminated in
cleavage of caspase-9 and activation of the intrinsic apoptosis cascade (Fig 3C).
Strictinin represses TNBC cell motility
ROR1 has similarly been shown to promote TNBC cell motility [32,33]. We sought out to
investigate if strictinin by inhibiting ROR1 activity might repress cell migration and invasion.
Fig 3. Strictinin induces apoptosis and reduces cell survival. a, b) Annexin-V/FITC staining and FACS to assess apoptosis in
MDA-MB-231 after treatment with strictinin. b) Quantification of strictinin induction of apoptosis (top and bottom right
quadrants) in both TNBC lines and non-malignant MCF-10A line. c) Immunoblots investigating modulation of pro- and anti-
apoptotic proteins downstream of ROR1 after strictinin treatment.
https://doi.org/10.1371/journal.pone.0217789.g003
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Wound healing assays suggest strictinin treatment repressed MDA-MB-231 and BT-549
migration and invasion in a dose-dependent manner (Fig 4A, 4B, 4D and 4E). We also con-
ducted control cell viability assays to ensure changes in cell migration weren’t as a result
of proliferation and confirmed no significant change in cell viability or numbers at the stricti-
nin doses and times assessed (3-12h, 62.5 and 125 μg/ml) (Fig 4C). MCF-10A, which are nor-
mally non-migratory, showed no significant change in migration after strictinin treatment (S3
Fig).
Fig 4. Strictinin represses TNBC cell motility. a) Wound healing assay investigating strictinin effect on MDA-MB-231 migration. b) Quantification of
wound healing assays in two TNBC lines and non-malignant MCF-10A. c) MTT viability assay to investigate proliferation and viability during wound
healing assay. d) Transwell assay investigating effect of strictinin on TNBC cell invasion. e) Quantification of transwell assay assessing strictinin effect on
TNBC cell invasion. (� = p.value< 0.05, n = 3).
https://doi.org/10.1371/journal.pone.0217789.g004
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Strictinin effect on cell migration is regulated via GSK3ß in a ß-catenin
independent manner
ROR1 is a non-canonical Wnt receptor which suggests it functions in a ß-catenin-independent
manner but because strictinin, via its action on AKT, induced such dramatic changes in
GSK3ß phosphorylation, a key member of the ß-catenin destruction complex, we opted to ver-
ify if ß-catenin was being affected in any way. Immunoblots revealed no changes in ß-catenin
phosphorylation on serine-33/37, the residues usually phosphorylated by GSK3ß and the
destruction complex. We also noted no significant changes in whole ß-catenin levels suggest-
ing no increased degradation of the protein (Fig 5A). To verify the mechanism of strictinin
action on migration was ROR1-dependent, we conducted siROR1 knockdown wound healing
assays. Our results suggested siRNA knockdown of ROR1 repressed strictinin’s effect on
TNBC migration (Fig 5B). After transfection, there was a partial rescue in cell migration even
after strictinin treatment. GSK3ß is a key regulator of the cell motility and so we opted to verify
if the observed repression of cell migration was GSK3ß-dependent. We treated cells with stric-
tinin and/or LiCl, a known GSK3ß inhibitor, and monitored cell migration. We observed phe-
notypic rescue after treatment with LiCl and strictinin. LiCl partially repressed strictinin’s
inhibitory effect on cell migration but by itself repressed cell migration.
Discussion
Current chemotherapeutic agents for TNBC, including taxanes and anthracyclines have been
shown to be both hepatotoxic and cardiotoxic to patients [34,35] leading to disastrous side
effects and a decrease in therapy adherence. The development of novel targeted anti-TNBC
agents that can target TNBC with minimal effects on normal tissue is thus an especially vital
mission in our efforts to treat the disease. Oncofetal receptors which are minimally expressed
in normal adult tissue but overexpressed in most cancers are appealing candidates for the
development of these targeted agents. One such receptor is the ROR1 receptor which is highly
expressed in most human malignancies but only minimally in normal tissue [9]. ROR1 has
emerged recently as a molecule of significant interest for the development of targeted small
molecules, antibodies, chimeric antigen T-cells and other agents for cancer therapy [15–17]. In
this study we describe the mode of action of strictinin, one such targeted agent, which inhibits
Fig 5. Strictinin effect on cell migration is GSK3ß and ROR1 -dependent but ß-catenin independent. a) Wound healing assay investigating strictinin effect
on MDA-MB-231 migration after siROR1 knockdown. b) Immunoblot investigating beta-catenin phosphorylation and degradation by the destruction
complex after treatment with strictinin. c) Wound healing assay investigating phenotypic rescue of migration by inhibition of GSK3ß after strictinin treatment
in MDA-MB-231. (� = p.value<0.05, n = 3).
https://doi.org/10.1371/journal.pone.0217789.g005
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the action of ROR1, repressing TNBC migration and survival via P13K/AKT/GSK3ß
deregulation.
To identify molecular targets for strictinin, we opted to use a non-blinded screening
approach by searching DrugBank. DB03008, a molecule very similar in structure to strictinin
(same glucopyranose backbone with branching galloyl subgroups), was previously shown to
have high affinity for ROR1 in an in silico drug discovery screen for possible ROR1 antagonists
[7]. It has also been shown to disrupt the activity of pathways downstream to ROR1 such as
P13K/AKT in breast cancer [36]. We hypothesized that strictinin, might similarly interact with
ROR1, inhibiting its function and disrupting the activity of pathways downstream to it.
We conducted a similar in silico docking experiment to the one performed by Nath et al [7]
and our results suggested strictinin may have affinity for ROR1. We confirmed strictinin and
ROR1 interaction by ITC and monitoring Wnt5a binding to ROR1 in presence of strictinin.
To further validate these findings, we transiently knocked down ROR1 expression in our
TNBC lines via siRNA and found a reduction in strictinin cytotoxicity in these lines. This
would suggest ROR1 is a target for strictinin in TNBC and high expression of ROR1 might be
partially necessary for strictinin-mediated cell death. Further corroborating these data, is the
fact that the non-tumorigenic line, MCF-10A, which only minimally expresses ROR1, shows
significant resistance to strictinin-induced cytotoxicity [4].
ROR1 signaling promotes breast cancer migration and survival via downstream activation
of the P13K/AKT pathway [8] resulting GSK3ß inhibition. Upon binding of the Wnt5a ligand,
ROR1 recruits CK1ε and promotes P13K-mediated phosphorylation of AKT on ser473.
Highly active p-AKT promotes survival by inhibiting apoptosis. Through its phosphorylation
of Bad on ser136, it prevents heterodimerization of Bad, Bax and Bak in the inner mitochon-
drial membrane to form a channel for Cytochrome C escape into the cytoplasm [37,38]. It also
phosphorylates XIAP allowing it to evade the Ubiquitin-Proteasome System (UPS). Stabilized
XIAP then directly inhibits the action of initiator caspase-9 and executioner caspase-3, repress-
ing apoptosis [39]. Highly active p-AKT also phosphorylates GSK3ß on ser9, directly repress-
ing its kinase activity [37]. GSK3ß is a negative regulator of cell migration by its repressive
action on microtubule growth via phosphorylation and inhibition of CLASP. It also phosphor-
ylates and inhibits FAK, inhibiting nascent adhesion turnover, a vital process to cell motility
[40,41].
Using both immunoblots and luciferase reporter assays we confirmed inhibition of AKT
phosphorylation on ser473 after strictinin treatment in both TNBC lines. This coincided with
a reduction in GSK3ß phosphorylation on ser9. Expectedly, in both TNBC lines we observed
an increase in apoptosis induction and decrease in cell survival after strictinin treatment. Inter-
estingly, in the non-malignant MCF-10A line, strictinin seemed to promote AKT phosphory-
lation with no noticeable effect on apoptosis induction or survival. This suggests strictinin’s
inhibitory effect on the P13K/AKT pathway is specific to the TNBC lines presumably due to
the presence of the ROR1 receptor. Immunoblots also revealed the method of apoptosis induc-
tion was intrinsic. There was a decrease in Bad phosphorylation on ser136, presumably allow-
ing it to heterodimerize with Bak and Bax forming a channel in the mitochondrial membrane
for cytochrome-C escape. When cytochrome-C is released into the cytoplasm, it binds to
Apaf-1 to form the apoptosome which cleaves caspase-9, activating it [42]. We observed an
increase in caspase-9 cleavage after strictinin treatment, indicative of induction of intrinsic
apoptosis.
To verify if strictinin’s inhibition of ROR1 and GSK3ß phosphorylation had any effect on
cell motility, we performed wound healing and transwell assays. Our results confirmed that
strictinin repressed TNBC cell migration and invasion. We performed the same experiment in
the non-malignant MCF-10A line and saw no noticeable effect on cell motility. This was
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expected as MCF-10A are a highly sedentary cell line, which much like most mature differenti-
ated cells, migrate only minimally. We also conducted migration experiments after siRNA
knockdown of ROR1 to assess if strictinin-mediated repression of cell motility was ROR1-de-
pendent. We observed rescue of phenotype suggesting ROR1 expression is vital to strictinin
action on cell motility. Similarly to our cell survival findings, strictinin’s lack of effect on MCF-
10A motility, which only minimally express ROR1, further supports this hypothesis.
GSK3ß is a key upstream regulator of cell motility so we assessed whether strictinin’s effect
on motility, was GSK3ß-mediated. The rationale for this was an abundance of previous work
emphasizing GSK3ß’s key role in regulating cell spreading and motility [41,43–45]. Phosphor-
ylation of GSK3ß on ser9 has also been shown to promote cell motility by repressing GSK3ß
kinase activity [46]. Using LiCl, a well-established GSK3ß inhibitor, in combination with stric-
tinin, we observed phenotypic rescue when compared to strictinin treatment alone. This sug-
gests strictinin’s effect on motility, in addition to being ROR1-dependent might be mediated
via its action on GSK3ß. Presumably, the “newly” reactivated GSK3ß after strictinin treatment,
was inhibited by LiCl, resulting in increased cell motility. Interestingly, we observed a decrease
in migration in the group treated with LiCl alone when compared to a vehicle control. Repres-
sion of GSK3ß beneath basal levels can occasionally have the adverse effect of repressing cell
motility. In at least one instance, GSK3ß has been shown to occasionally form a complex with
cytoplasmic cyclic AMP to promote focal adhesion turnover and facilitate cell motility, a direct
contrast to its usual effect on focal adhesions [45]. In such cases, repressing GSK3ß beneath
basal levels could repress cell motility. Further studies are however warranted to appreciate the
effects of GSK3ß inhibition on TNBC motility.
In summary, we describe the mechanism of action of strictinin, a novel ROR1-inhibitor
which was previously shown to selectively target TNBC cells with minimal effects on non-
malignant cells. This could be of potential therapeutic interest considering heightened interest
in ROR1 and other receptor tyrosine kinases as targets for development of anti-cancer agents.
Further studies are needed to validate these findings in other ROR1-expressing malignancies
but also in more systemic models of TNBC. Our findings do however underline the potential
of strictinin and other ROR1-targeting agents as therapeutic tools to reduce TNBC prolifera-
tion, survival and motility.
Supporting information
S1 Fig. Strictinin and DB03208 interact with ROR1 at similar binding sites. a) SiteMap
active site of tROR1 with several key residues labelled. b, c) DB03208 docked to tROR1 and
ligand interactions diagram. Whereas N-terminus is indicated by a red ball, C-terminus is
indicated by a blue ball. d) Strictinin (green) and DB03208 (yellow) dockings superimposed.
ITC experiment was prepared with 13.8 μM ROR1 in the ITC cell and 276 μM strictinin in the
syringe. Experiment was performed at 37˚C in (0.1% DMSO in molecular grade water) using
the Affinity ITC (TA Instruments). Raw binding data (upper panel) were analyzed and fit
(lower panel) using NanoAnalyze (TA Instruments). Binding parameters, included as an inset
(upper panel), indicate an enthalpically driven 1-to-1 binding interaction.
(TIFF)
S2 Fig. Strictinin inhibits AKT phosphorylation and downstream GSK3ß phosphorylation
independent of CK1ε. a). FOXO-luciferase assay assessing strictinin effect on P13K/AKT
activity in BT-549 after 24h. (� = p.value< 0.05, n = 3) b) Co-Immunoprecipitation of ROR1
to assess CK1ε binding after strictinin treatment.
(TIF)
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S3 Fig. Strictinin does not affect non-malignant MCF-10A cell motility. Wound healing
assay investigating strictinin effect on MCF-10A migration (� = p.value < 0.05, n = 3).
(TIF)
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